Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance

• Céline Narjoz,

  Affiliations Université Paris Descartes, INSERM UMR S-U775, Sorbonne Paris Cité, Paris, France, Hôpital Européen Georges Pompidou, Service de Biochimie, Unité Fonctionnelle de Pharmacogénétique et Oncologie Moléculaire, Paris, France

  ⨯
• Amélie Favre,

  Affiliation Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

  ⨯
• Justin McMullen,

  Affiliation Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

  ⨯
• Philippe Kiehl,

  Affiliation Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

  ⨯
• Michael Montemurro,

  Affiliation University Hospital Zürich, Oncology, Zürich, Switzerland

  ⨯
• William D. Figg,

  Affiliation Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Philippe Beaune,

  Affiliations Université Paris Descartes, INSERM UMR S-U775, Sorbonne Paris Cité, Paris, France, Hôpital Européen Georges Pompidou, Service de Biochimie, Unité Fonctionnelle de Pharmacogénétique et Oncologie Moléculaire, Paris, France

  ⨯
• Isabelle de Waziers,

  Affiliation Université Paris Descartes, INSERM UMR S-U775, Sorbonne Paris Cité, Paris, France

  ⨯
• Bertrand Rochat

  * E-mail: bertrand.rochat@chuv.ch

  Affiliation Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

  ⨯